Dec 22, 2020 3:00am Drug manufacturers are looking for a more local future for production post-COVID-19. (Pixabay)(Monica Alleven/Fierce Wireless) With the COVID-19 pandemic perhaps entering its final phase as the first wave of vaccines approaches the market, one question left unanswered is the future of "onshoring" drug manufacturing—an initiative that reached fever pitch in 2019 as nationwide lockdowns and geopolitical tension cast a spotlight on the global supply chain. In 2019, congressional leaders across the aisle picked up steam on a suite of bills aimed at incentivizing and driving manufacturing redundancy in the U.S. to combat China and India's dominance in generic medicines and active pharmaceutical ingredients (APIs).